Sotagliflozin, a drug recently approved ... with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib ...

Chemotherapy acts directly on cancer ... cell lung cancer. Although immunotherapy is a newer class of treatment, insurance programs, including Medicare, will often cover immunotherapy drugs.

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

TUESDAY, Feb. 4, 2025 (HealthDay News) — For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted ...

For lung cancer, we are in the process of shifting to immunotherapy and targeted therapy based on gene panel tests. It has improved the survival rate and period, as well as the patients' quality ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

“The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look ...

Non–small cell lung cancer ... BRAF or MEK inhibitors against non-V600E BRFA mutant NSCLC (73). Any significant association between HER2 mutations and HER2 amplification could not be found. Initial ...